We recently demonstrated that RASSF1A, a new tumoursuppressor gene located at 3p21.3 is frequently inactivated by promoter region hypermethylation in a variety of human cancers including lung, breast, kidney and neuroblastoma. We have identified another member of the RASSF1 gene family by in silico sequence analysis using BLAST searches. NORE1 located at 1q32.1 exists in three isoforms (NORE1Aa, NORE1Ab and NORE1B). Both NORE1A and NORE1B isoforms have separate CpG islands spanning their first exons. NORE1Aa Produces a 418 aa protein containing a Ras-association (RA) domain and a diacylglycerol (DAG) binding domain. NORE1Ab produces a C-terminal truncation of the RA domain. NORE1B also contains the RA domain but not the DAG domain. NORE1 is the human homologue of the mouse Ras effector Nore1. No inactivating somatic mutations were found in lung tumour lines; however, NORE1A promoter region CpG island was hypermethylated in primary tumours and tumour cell lines. NORE1A promoter was methylated in 10/25 breast, 4/40 SCLC, 3/ 17 NSCLC, 1/6 colorectal and 3/9 kidney tumour cell lines, while NORE1B promoter was unmethylated in the same tumour cell lines. While 24% (6/25) of primary NSCLC underwent NORE1A methylation, methylation in SCLC was a rare event (0/22); (P ¼ 0.0234). NORE1A expression in tumour cell lines was reactivated after treatment with a demethylating agent. There was no correlation between NORE1A and RASSF1A methylation status in NSCLC. Our results demonstrate that NORE1A is inactivated in a subset of human cancers by CpG island promoter hypermethylation, and in lung cancer this hypermethylation may be histological type specific. Oncogene (2003) 22, 947-954.
Introduction
Many diseases including cancer involve disruption of signalling pathways. Ras-signalling pathway plays important roles in tumorigenesis. Mutations in the Ras oncogene have been found frequently in many tumour types including lung, colorectal and gastric cancer. The Ras superfamily of small GTP-binding proteins play a fundamental role in signal transduction pathways governing cell growth and differentiation, membrane trafficking, transcriptional regulation and apoptosis. They exist in an inactive, GDB-bound and an active GTP-bound conformation. In the active GTP-bound state, Ras interacts with its downstream effectors to promote a cellular response (Campbell et al., 1998; Downward, 2001) . Several of these Ras effectors have a common Ras-association (RA) domain (Ponting and Benjamin, 1996) Recently, we and others have identified a new family of genes encoding RAS-binding proteins, RASSF1. RASSF1 is located within the 120 kb critical region at 3p21.3 containing overlapping homozygous deletions in lung and breast tumour cell lines (Lerman and Minna, 2000; Dammann et al., 2000) . It has several major isoforms due to alternative splicing and differential promoter usage. RASSF1C is the shorter isoform, and is well expressed in tumour cell lines. While the expression of the longer isoform, RASSF1A, is lost in many tumour lines and primary tumours. Loss of RASSF1A expression correlates with the methylation of a CpG island in its promoter region, while RASSF1C promoter region CpG island remains unmethylated (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001) . RASSF1A promoter region hypermethylation has been demonstrated in lung, breast, kidney, prostate, neuroblastoma, nasopharyngeal, gastric, bladder primary tumours and tumour cell lines Burbee et al., 2001; Byun et al., 2001; Dammann et al., 2001; Dreijerink et al., 2001; Lee et al., 2001; Lo et al., 2001; Morrissey et al., 2001; Astuti et al., 2001; Maruyama et al., 2002) . In addition, RASSFIA suppresses the growth of tumour cell lines in both in vitro and in vivo studies (Burbee et al., 2001; Dammann et al., 2000) . Both isoforms contain a predicted ras-association domain; in addition, RASSF1A also contains a pre-dicted diacylglycerol binding domain also found in the mouse Ras effector gene nore 1 (Vavvas et al., 1998) and the rat homologue, maxp 1.
We used sequence homology searches to look for further genes containing a ras association domain. We identified three isoforms of the human homologue (NORE1, located at 1q32.1) of the mouse nore 1 gene. We analysed NORE1 for somatic mutations in tumour cell lines and investigated expression and methylation status of NORE1A and NORE1B promoters in primary tumours and tumour cell lines.
Results
In Silico characterization and sequencing of NORE1 isoforms BLAST searches were used to identify genes related to RASSF1 gene family containing RA domain. We identified three isoforms of the NORE1 gene located at 1q32.1, which is the human homologue of the mouse nore 1 gene. Largest of the ESTs (BG333910) was completely sequenced, it contained an open reading frame of 1254 nucleotides, a stop codon at 1314 and a polyA signal beginning at 3481. This EST represented NORE1Aa. NORE1Aa produces a 418 aa protein containing an N-terminal DAG domain and a carboxy-terminus RA domain (Figure 1a ). ClustalW alignment shows that there is a 45% similarity between NORE1Aa and RASSF1A. NORE1Ab differs from NORE1Aa in that it contains a C-terminal truncation of the RA domain producing a protein of 336 aa. NORE1B (265 aa) contains the RA domain but not the DAG domain and is transcribed from a different promoter as compared to NORE1A (Figure 1a) , there is 85% similarity at the aa level between NORE1A and NORE1B.
We analysed expression of NORE1Aa and NORE1B in normal human tissues using specific primers for the two isoforms. The Multiple Tissue cDNA (MTC) panel 1 (Clontech) containing cDNA from several normal human tissues was used as well as a cDNA from a normal breast cell line. As seen from Figure 1b both NORE1Aa and NORE1B are well expressed in normal lung, brain, placenta, liver, pancreas and breast. While lower expression is seen in kidney and skeletal muscle, NORE1Aa is either expressed very weakly or not expressed at all in normal heart.
NORE1A is silenced by promoter region hypermethylation in tumour cell lines
We analysed lung, breast, colorectal and kidney tumour cell lines for NORE1A and NORE1B promoter region CpG island hypermethylation using COBRA assay. Figures 2a and 3a show the sequence of the two promoters and COBRA primer locations. The methylation analysis was carried out as described in Agathanggelou et al. (2001) . In all, 3/17 (18%) NSCLC, 4/40 (10%) SCLC, 10/25 (40%) breast, 1/6 (17%) colorectal and 3/9 (33%) kidney tumour cell lines were methylated for NORE1A (Figure 4 ), while none of these tumour lines showed NORE1B promoter region CpG island methylation. The COBRA PCR products were cloned and sequenced to determine the pattern and extent of methylation (Figures 2b and 3b) . For NORE1A majority of the CG dinucleotides were methylated hence confirming our COBRA results (Figure 2b ), while COBRA products for NORE1B CpG island were unmethylated ( Figure 3b ). Majority of methylated tumour cell lines had either absence or downregulation of NORE1A expression (Figure 5a ), while there was no loss of expression in these tumour cell lines for NORE1B (Figure 5b ). To establish that methylation was responsible for silencing NORE1A isoform, we treated a colorectal (SW48) and a breast (HCC1419) tumour cell line both methylated for NORE1A, and a breast (HTB-19) tumour line unmethylated for NORE1A with the demethylating agent 5-aza-dc. NORE1A expression was upregulated after 5-aza treatment in SW48 and HCC1419 tumour cell lines but had no effect on HTB-19 expression ( Figure 5c ).
NORE1 gene is not commonly mutated in lung tumour cell lines
We analysed all coding exons of both NORE1A and NORE1B by PCR-SSCP in 20 lung tumour cell lines without NORE1 methylation. The intronic primers for mutation analysis were determined by aligning cDNA and genomic sequences. No somatic inactivating mutations were found but two missense changes were identified (exon 1alpha: nt106 TTG>CTG, Leu17>-Leu17 in 2/20 lung lines; Exon 4: CGG>AGG, Arg277>Arg277 in 1/20 lung lines).
NORE1A methylation in primary lung tumours
We used COBRA and/or MSP assays to establish the frequency of NORE1 methylation in primary lung tumours. NORE1A methylation was detected in 6/25 (24%) NSCLC, 0/22 SCLC primary tumours (P ¼ 0.0234), while NORE1B methylation was not detected in any of these tumours ( Figure 6 ). No methylation for NORE1A was detected in DNA from corresponding normal lung tissue.
Relation between NORE1A and RASSF1A methylation status
In an earlier study we had analysed the same series of primary SCLC and NSCLC for RASSF1A methylation. A total of 72% of SCLC and 34% of NSCLC tumours were found to be methylated for RASSF1A . Of the 22 SCLC analysed, 13 were methylated for RASSF1A, seven were unmethylated and for two RASSF1A methylation status was not determined. None of these SCLC were found to be methylated for NORE1A. Of the six NSCLC tumours methylated for NORE1A, two were also methylated for RASSF1A (P ¼ 1.000).
NORE1A, a homologue of RASSF1A tumour suppressor gene L Hesson et al Figure 1 (a) A the NORE1 gene is located at 1q32.1, occupies approx. 82 kb of genomic DNA (+strand) and encodes for at least three isoforms via alternative splicing (NORE1Aa and NORE1Ab) and differential promoter usage (NORE1A and NORE1B). NORE1Aa (BC007203/GI:13938171) produces a 3498 bp mRNA, NORE1Ab (AY062003/GI:17864749) produces a 3383 bp mRNA and NORE1B (AF445801/GI:17386087) produces a 3499 bp mRNA. The UCSC Human Genome Project Working Draft, April 2002 assembly, shows additional spliced ESTs. B NORE1Aa contains a DAG/PE binding domain and a C-terminus RA domain as predicted by Interpro and PPSearch programs. C NORE1Ab lacks exon 5, which results in a Cterminal truncation of the RA domain. D NORE1B lacks exons 1a and 2a, which are replaced by exon 2b. This results n a much shorter protein product with a different N-terminus that lacks the DAG/PE-binding domain present in the NORE1A isoforms. (b) Left panel, NORE1A expression in normal tissues. Right panel, NORE1B expression in normal tissues. 1 heart, 2 brain, 3 placenta, 4 lung, 5 liver, 6 skeletal muscle, 7 kidney, 8 pancreas and 9 breast Discussion Tumour-specific promoter CpG island hypermethylation has been recently shown to be a common inactivation mechanism for TSGs in human cancers (Baylin and Bestor, 2002; Jones and Baylin, 2002) . We and others have recently shown that isoform A of the novel 3p21.3 TSG RASSF1A is frequently inactivated almost exclusively by promoter region hypermethylation in a variety of tumor types (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001) . While the C isoform of RASSF1 is well expressed in tumour cell lines and primary tumours, its promoter region CpG island is unmethylated in these tumour cell lines and primary tumours. Both RASSF1A and RASSF1C contain the RAS association domain; there are two contradictory reports in the literature one showing direct binding to Ras (Vos et al., 2000) and the other demonstrating no direct interaction between RASSF1 and Ras or six other Ras GTPases (Ortiz-Vega et al., 2002) . Hence, it remains to be determined if they bind directly to Ras in a GTP-dependent manner, both in in vitro and in vivo studies. In this report we describe in silico identification and characterization of another member of the RASSF gene family, namely NORE1. NORE1 is the human homologue of the mouse nore 1 gene, a known Ras effector. Human NORE1 has at least three isoforms because of alternative splicing and differential promoter usage. NORE1 is well expressed in a variety of normal human tissues. We analysed the two CpG islands, one specific for NORE1A isoform and the other specific for NORE1B isoform in a range of tumour cell lines. We demonstrated that methylation of NORE1A CpG island occurs in lung, breast, colorectal and kidney tumour cell lines and in primary NSCLC tumours (24%), but no methylation was found in primary SCLC tumours (P ¼ 0.0234). We did not find any methylation of NORE1B CpG island in the above tumour cell lines. Our data suggests that NORE1A methylation in lung tumours may be histological type specific. Furthermore in tumour cell lines, expression of NORE1A was restored after treatment with a demethylating agent, confirming that loss of expression is due to promoter hypermethylation. We also demonstrated by direct sequencing of modified DNA from methylated tumour lines that majority of the CG dinucleotides analysed were methylated. No somatic inactivating mutations were found in 20 lung tumour cell lines that did not demonstrate NORE1A methylation. A recent article by Tommasi et al. (2002) described identification and methylation/mutation analysis of NORE1 gene. In agreement with our results they did not find any inactivating mutations in NORE1 in lung tumours. Tommasi et al, report that they did not find any methylation in lung tumour cell lines or melanoma and (2002) demonstrated that neither RASSF1A nor RASSF1C are able to bind directly to Ras or six other Ras GTPases. But that RASSF1A homodimerizes and heterodimerizes with Nore1 through its nonhomologous aminoterminal segment, while RASSF1C exhibits much weaker interaction. Furthermore, a recent article describes binding of NORE1 and RASSF1 to the proapoptotic protein kinase MST1 and demonstrates that NORE-MST1 complex is a novel Ras effector, which mediates the apoptotic effect of KiRasG12 V .
In this article we have demonstrated that isoform A of NORE1, a known Ras-effector, is inactivated in a variety of tumour cell lines and primary NSCLC tumours by promoter region CpG island hypermethylation and that in lung cancer NORE1A inactivation may be histological type specific. Hence, another member of the ras-association domain gene family is inactivated in human cancers, further implicating the Ras signal transduction pathway in tumorigenesis. Furthermore, our data warrants detailed analysis in human cancers of the other RA domain containing family members.
Materials and methods

Tumour samples
A total of 25 NSCLC and 15 SCLC tumour samples and corresponding normal tissue and 7 NSCLC, 40 SCLC, 25 breast, six colorectal and nine kidney tumour cell lines were analysed for NORE1A and NORE1B CpG island methylation. Tumours and cell lines have been described previously Morrissey et al., 2001) .
Bisulphite modification and methylation analysis
Bisulphite DNA sequencing was performed as described previously . Briefly, 0.5-11.0 mg of genomic DNA was denatured in 0.3 m NaOH for 15 min at 371C. Unmethylated cytosine residues were then sulphonated by incubation in 3.12 m sodium bisulphite (pH 5.0) (Sigma) and 5 mm hydroquinone (Sigma) in a thermocycler (hybaid) for 15 s at 991C and 15 min at 501C for 20 cycles. Sulphonated DNA was then recovered using the Wizard DNA cleanup system (Promega) according to the manufacturer's instructions. The DNA was desulphonation by addition of 0.3 m NaOH for 10 min at room temperature. The converted DNA was then ethanol precipitated and resuspended in water.
The NORE1A putative promoter region was predicted by Promoter Inspector software (www.genomatix.de). This region is from À714 bp to +465 bp relative to the transcription start site. The region was amplified with nested PCR using primers described in Figure 2a . 1/100 volume of the first PCR reaction (obtained using the primers NORE1A CoBRA F and NORE1A CoBRA R) was added to a second PCR reaction using the nested primer (NORE1A CoBRA FN plus NORE1A CoBRA R). The conditions for both PCR reactions were 941C for 10 min followed by 30-35 cycles of denaturation for 1 min at 941C, annealing for 1 min at 541C and extension for 2 min at 741C.
The methylation-sensitive PCR was performed using the primers described in Figure 2a . The PCR cycling conditions for the MSP assay were 951C for 10 min followed by 40 cycles of denaturation for 1 min at 951C, annealing for 1 min at 621C and extension for 2 min at 741C. The unmethylated allele was amplified using the same conditions but with annealing temperature of 541C and using the primers The NORE1B putative promoter region was predicted by Promoter Inspector software. This region is from À195 bp to +315 bp relative to the transcription start site. The region was amplified with nested PCR using primers described in Figure 3a . A 2/100 volume of the first PCR reaction (obtained using the primers NORE1B CoBRA F and NORE1B CoBRA R) was added to a second PCR reaction using the nested primers (NORE1B CoBRA FN plus NORE1B CoBRA RN). The conditions for both PCR reactions were 941C for 10 min followed by 30-35 cycles of denaturation for 1 min at 941C, annealing for 1 min at 541C and extension for 2 min at 741C.
Cell lines and 5-aza-2 0 deoxycytidine treatment Lung, breast and colorectal cell lines were routinely maintained in RPMI 1640 growth media (Invitrogen) supplemented with 10% FCS at 371C, 5% CO 2 . Cells 5À10 Â 10 5 were plated and allowed 24 h growth before addition of 5-aza-2 0 -deoxycytidine (Sigma). The medium was changed 24 h after treatment and then every 3 days. RNA was prepared at 5 and 7 days after treatment using the RNeasy kit (Qiagen) according to the manufacturer's instructions.
NORE1A expression analysis
Tumour cell lines were analysed for NORE1Aa expression using RT-PCR (Amersham Biosciences). Primers used were specific for exon 2a (5 0 -ATCCAGTTGGACTGCAGTCA-3 0 ) and exon 4 (5 0 -GGGATTGTCCACAACCATG-3 0 ) to give an RT-PCR expression analysis of NORE1B using exon 2b (forward) and exon 4 (reverse) primers. All lines showed high levels of expression that correlates with the lack of methylation found in the NORE1B CpG island. Lane 1 SW48, 2 LS411, 3 HCT 116, 4 HCC1419, 5 MCF-7, 6 LoVo, 7 A549, 8 T47D. (c) 1 SW48, 2 SW48 5-aza treated, 3 HCC1419, 4 HCC1419 5-aza treated. 5-aza treatment restores NORE1A expression in SW48 and HCC1419. 5 HTB19, 6 HTB19 5-aza treated; 5-aza treatment has no effect on NORE1A expression in unmethylated cell lines A methylated colorectal and a methylated breast carcinoma cell line plus one unmethylated breast carcinoma cell line were treated with 10 mm demethylating agent 5-aza-2 0 -deoxycytidine, freshly prepared in ddH20 and filter-sterilized.
NORE1B expression analysis
Four colorectal, one lung and three breast cell lines were analysed for NORE1B expression using RT-PCR. Primers used were specific for exon 2b (5 0 -CTGCTTCTTCACTGC-TAAGAC-3 0 ) and exon 4 (5 0 -GGGATTGTCCACAAC-CATG-3 0 ) to give an expected product size of 425 bp. In all RT-PCR reactions the expression of GAPDH was used as a positive control. The primers used for GAPDH were 5 0 -TGAAGGTCGGAGTCAACGGATTTGGT-3 0 and 5 0 -CATGTGGGCCATGAGGTCCACCAC-3 0 to give an expected product size of 982 bp. Multiple tissue cDNA (MTC) panel I (Clontech) was used for expression analysis in normal tissues using the above specific primers for NORE1A and NORE1B.
Mutation analysis of lung tumour cell lines
All exons of the NORE1 gene were analysed using PCR-SSCP in 15 SCLC and five NSCLC tumour cell lines using intronic primers designed from the Human Genome Working Draft Sequence at UCSC (http://genome.cse.ucsc.edu). Aberrantly migrating bands were sequenced using an ABI 377 automated sequencer.
